Navigation Links
WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
Date:6/28/2009

SHANGHAI, June 29 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) announced today that it had been selected by China's Ministry of Commerce to the list of Top Ten Leading Outsourcing Enterprises in China. The list was announced at the Second Annual China International Service Outsourcing Cooperation Conference, held in Nanjing on June 23 and 24, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

According to the ministry, revenue generated by Chinese outsourcing companies in 2008 grew 34% year over year to $1.5 billion. The top ten companies produced almost one third of that revenue. Those companies represented the healthcare, service and manufacture, government, education and finance sectors. WuXi PharmaTech was the only winner in healthcare.

"We are honored to receive this recognition by the Ministry of Commerce," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "Outsourcing benefits not only China by tapping the skills and talents of our country's productive workforce, but also benefits countries around the world with high-quality, cost-effective products and services provided by outsourcing service companies. We are grateful to the Ministry of Commerce for its generous support of WuXi and the outsourcing industry in general. With continued support, we will continue to develop both capabilities and capacity to better serve the world's leading life science companies."

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, we provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners to improve the success of research and shorten the time of development cost effectively in discovering and developing drugs and medical devices.

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com

     Web:http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
2. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
3. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
4. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
5. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
6. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
7. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
8. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
9. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
10. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
11. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
Breaking Biology News(10 mins):